AVROBIO

$10.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today

-$0.22 (-2.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AVROBIO and other stocks, options, and ETFs commission-free!

About AVRO

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA. The listed name for AVRO is AVROBIO, Inc. Common Stock.

CEO

Geoff MacKay

Employees

—

Headquarters

Cambridge, Massachusetts

Founded

2015

Market Cap

459.69M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.42M

High Today

$11.16

Low Today

$10.59

Open Price

$10.99

Volume

877.07K

52 Week High

$23.50

52 Week Low

$9.76

Analyst Ratings

88%

of 8 ratings

Buy

88%

Hold

13%

Sell

AVRO Earnings

-$1.01

-$0.67

-$0.34

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 15, Pre-Market